Tu1729 EFFICACY OF RISANKIZUMAB BY BASELINE CLINICAL, BIOCHEMICAL, AND ENDOSCOPIC DISEASE SEVERITY IN MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
Gastroenterology(2023)
关键词
risankizumab by baseline clinical,severely active crohns,endoscopic disease severity,tu1729 efficacy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要